This company is no longer active
Aerie Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Key information
13.7%
Earnings growth rate
18.2%
EPS growth rate
Pharmaceuticals Industry Growth | 7.3% |
Revenue growth rate | 53.6% |
Return on equity | n/a |
Net Margin | -17.1% |
Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Aerie Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 22 | 214 | -37 | 130 | 88 |
30 Jun 22 | 207 | -49 | 130 | 85 |
31 Mar 22 | 201 | -69 | 137 | 83 |
31 Dec 21 | 194 | -75 | 138 | 76 |
30 Sep 21 | 104 | -166 | 137 | 74 |
30 Jun 21 | 95 | -166 | 134 | 71 |
31 Mar 21 | 86 | -176 | 133 | 73 |
31 Dec 20 | 83 | -183 | 137 | 74 |
30 Sep 20 | 83 | -192 | 138 | 76 |
30 Jun 20 | 82 | -202 | 138 | 82 |
31 Mar 20 | 79 | -201 | 139 | 82 |
31 Dec 19 | 70 | -200 | 138 | 81 |
30 Sep 19 | 60 | -196 | 135 | 87 |
30 Jun 19 | 48 | -232 | 135 | 94 |
31 Mar 19 | 35 | -240 | 134 | 91 |
31 Dec 18 | 24 | -233 | 121 | 86 |
30 Sep 18 | 10 | -240 | 94 | 98 |
30 Jun 18 | 2 | -187 | 81 | 82 |
31 Mar 18 | 0 | -160 | 65 | 74 |
31 Dec 17 | 0 | -145 | 57 | 72 |
30 Sep 17 | 0 | -116 | 66 | 48 |
30 Jun 17 | 0 | -107 | 57 | 48 |
31 Mar 17 | 0 | -102 | 49 | 51 |
31 Dec 16 | 0 | -99 | 35 | 52 |
30 Sep 16 | 0 | -90 | 37 | 51 |
30 Jun 16 | 0 | -84 | 34 | 48 |
31 Mar 16 | 0 | -80 | 32 | 45 |
Quality Earnings: 0P0 is currently unprofitable.
Growing Profit Margin: 0P0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0P0 is unprofitable, but has reduced losses over the past 5 years at a rate of 13.7% per year.
Accelerating Growth: Unable to compare 0P0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0P0 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (18.7%).
Return on Equity
High ROE: 0P0's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.